New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...
Legend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese ...
Newly created position to lead efforts focused on continued growth and salesSOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell ...
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Legend Biotech (LEGN – Research ...
Hosted on MSN12d
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to TradeLegend Biotech Corporation Sponsored ADR (LEGN) closed the last trading session at $43.95, gaining 0.9% over the past four ...
Legend Biotech has reduced Genscript Biotech's control, lowering its voting power below 50%, amid growing US scrutiny of ...
On Wednesday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $43.95 which represents a decrease of $-1.08 or -2.40% from the prior close of $45.03. The stock opened at $44.71 and ...
SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader ...
AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...
Zacks.com on MSN1d
Gilead Science to Report Q3 Earnings: What's in the Cards?Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around. Legend ...
The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback